Product Description

Active Substance:

• Meloxicam: 5 mg

Excipient:

• Ethanol: 150 mg

Therapeutic Indications:

• Dogs: Relief of inflammation and pain in acute and chronic musculoskeletal disorders. Reduction of postoperative pain and inflammation resulting from orthopaedic and soft tissue surgery.
• Cats: Reduction of postoperative pain following ovariohysterectomy and minor soft tissue surgery.
• Cattle: For use in acute respiratory infections with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves over one week of age and young non-lactating cattle, for the alleviation of postoperative pain following dehorning in calves.
• Swine: For use in non-infectious locomotor disorders to reduce symptoms of lameness and inflammation, for the alleviation of postoperative pain associated with minor surgical operations of soft tissues, such as castration.

Intended Animal Species for Veterinary Medicinal Product (VMP):

• Dogs, cats, cattle (calves and young cattle), and swine.

Contraindications:

• Do not use in case of hypersensitivity to the active substance or any of the excipients. Do not apply to pregnant and lactating dogs and cats.
• Do not use in dogs and cats suffering from gastrointestinal disorders such as inflammation and haemorrhage, impaired liver, heart, or kidney function, and hemorrhagic disorders. Do not use in dogs and cats under six weeks of age and in cats weighing less than 2 kg.
• Do not use in cattle and swine suffering from impaired liver, heart, or kidney function and hemorrhagic disorders or in which there is evidence of ulcerogenic gastrointestinal lesions. Do not use it for the treatment of diarrhoea in cattle under one week of age. Do not use it on pigs under two days of age.

Adverse Reactions:

• In dogs and cats: Typical adverse reactions of nonsteroidal anti-inflammatory drugs (NSAIDs), such as loss of appetite, vomiting, diarrhoea, occult blood in stools, lethargy, and renal failure, are sometimes reported. In sporadic cases increased liver enzymes are reported. In dogs, in sporadic cases, there are reports of hemorrhagic diarrhoea, hematemesis, and gastrointestinal ulceration. In dogs, these side effects usually occur during the first week of treatment and, in most cases, are transient and disappear after the end of treatment, but in very rare cases, they can be severe or fatal. Infrequent anaphylactoid reactions may occur, which should be treated symptomatically.
• In cattle and swine: Subcutaneous, intramuscular, and intravenous administration are well tolerated; in less than 10% of the cattle treated in clinical studies, mild, temporary swelling at the injection site was observed after subcutaneous administration. In very rare cases, anaphylactic reactions may occur, which can be severe (including fatal) and should be treated symptomatically. In the case of adverse reactions, treatment should be discontinued and veterinary advice sought. If you notice any serious or other effects resulting from using this VMP that are not described in this leaflet, please immediately inform your veterinary doctor.

Dosage and Mode of Administration:

• Dogs: For musculoskeletal disorders: a single subcutaneous injection of 0.2 mg meloxicam/kg body weight (i.e., 0.4 ml/10 kg b.w.). Oral suspension of meloxicam for dogs may be used to continue treatment at 0.1 mg meloxicam/kg b.w. 24 hours after the injection. For the reduction of postoperative pain (for a period over 24 hours), a single intravenous or subcutaneous injection of 0.2 mg meloxicam/kg b.w. (i.e., 0.4 ml/10 kg b.w.) prior to surgery, for example, during induction of anaesthesia.
• Cats: To reduce postoperative pain, a single subcutaneous injection of 0.3 mg meloxicam/kg b.w. (i.e., 0.06 ml/1 kg b.w.) prior to surgery, for example, during induction of anesthesia.
• Cattle: a single intravenous or subcutaneous injection of 0.5 mg meloxicam/kg b.w. (i.e., 10 ml/100 kg b.w.) in combination with appropriate antibiotic therapy or oral rehydration therapy, as appropriate.
• Swine: a single intramuscular injection of 0.4 mg meloxicam/kg b.w for locomotor disorders. (i.e., 2 ml/25 kg b.w.). If necessary, repeat administration of meloxicam can be performed after 24 hours. To reduce postoperative pain, a single intramuscular injection of 0.4 mg meloxicam/kg b.w. (i.e., 0.4 ml/25 kg b.w.) prior to surgery.

Withdrawal Period:

• Cattle: Meat and offal: 15 days
• Swine: Meat and offal: 5 days